Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D-Reference-Cited by-同舟云学术

Patient and Payer Incentives to Use Patented Brand-Name Drugs vs Authorized Generic Drugs in Medicare Part D

Published:2021-12-01 Issue:12 Volume:181 Page:1605
ISSN:2168-6106
Container-title:JAMA Internal Medicine
language:en
Short-container-title:JAMA Intern Med

Author:

Dusetzina Stacie B.¹²,Sarpatwari Ameet³,Carrier Michael A.⁴,Hansen Richard A.⁵,Keating Nancy L.⁶⁷,Huskamp Haiden A.⁶

Affiliation:

1. Department of Health Policy, Vanderbilt University School of Medicine, Nashville, Tennessee

2. Vanderbilt-Ingram Cancer Center, Nashville, Tennessee

3. Program on Regulation, Therapeutics, and Law (PORTAL), Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women’s Hospital and Harvard Medical School, Boston, Massachusetts

4. Rutgers Law School, Camden, New Jersey

5. Auburn University Harrison School of Pharmacy, Auburn, Alabama

6. Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts

7. Division of General Internal Medicine, Brigham and Women's Hospital, Boston, Massachusetts

Publisher

American Medical Association (AMA)

Subject

Internal Medicine

Link

https://jamanetwork.com/journals/jamainternalmedicine/articlepdf/2785227/jamainternal_dusetzina_2021_oi_210061_1638550199.4317.pdf

Reference24 articles.

1. Eight reasons why “no-authorized-generic” promises constitute payment.;Carrier,2015

2. Authorized generics and their evolving role in prescription drug pricing and access.;Dusetzina;JAMA Intern Med,2021

3. Prescription drugs-list price, net price, and the rebate caught in the middle.;Dusetzina;JAMA,2019

4. Changes in list prices, net prices, and discounts for branded drugs in the US, 2007-2018.;Hernandez;JAMA,2020

5. Share of specialty drugs in commercial plans nearly quadrupled, 2003-14.;Dusetzina;Health Aff (Millwood),2016

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefit Design And Biosimilar Coverage In Medicare Part D: Evidence And Implications From Recent Reforms;Health Affairs;2024-05-01

2. Changes in Use of Hepatitis C Direct-Acting Antivirals After Access Restrictions Were Eased by State Medicaid Programs;JAMA Health Forum;2024-04-05

3. Market dynamics of authorized generics in Medicaid from 2014 to 2020;Health Services Research;2023-03-06